Biohaven Pharmaceutical

Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.

Launch date

Sep 2014

Employees

Market cap

Enterprise valuation

€2.9b (Public information from Sep 2024)

New Haven Connecticut (HQ)

http://biohavenpharma.com

https://twitter.com/biohaven https://www.facebook.com/biohaven https://www.linkedin.com/company/biohaven/

Authorizing premium user...